Tadalafil
- Generic Name
- Tadalafil
- Brand Names
- Adcirca, Alyq, Cialis, Entadfi, Tadliq, Talmanco (previously Tadalafil Generics), Tadalafil Mylan, Tadalafil Lilly, Adcirca (previously Tadalafil Lilly)
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19N3O4
- CAS Number
- 171596-29-5
- Unique Ingredient Identifier
- 742SXX0ICT
- Background
Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy. It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like sildenafil, tadalafil has greater selectivity fo...
- Indication
Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with finasteride for the treatment of benign prostatic hypertrophy (BPH). It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with macitentan or other endothelin-1 antagonists.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Erectile Dysfunction, Pulmonary Arterial Hypertension (PAH)
- Associated Therapies
- -
Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male Volunteers
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 17
- Registration Number
- NCT02253862
Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms
- Conditions
- Interventions
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- University of Florence
- Target Recruit Count
- 86
- Registration Number
- NCT02252367
- Locations
- 🇮🇹
Clinica Urologica - Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
Evaluating a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin
- Conditions
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 30
- Registration Number
- NCT02239484
- Locations
- 🇰🇷
Samgsung Seoul Hospital, Seoul, Korea, Republic of
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 10
- Registration Number
- NCT02225548
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 635
- Registration Number
- NCT02224846
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yinchuan, China
A Study of LY2623091 in Participants With High Blood Pressure
- Conditions
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 304
- Registration Number
- NCT02194465
- Locations
- 🇺🇸
Cor Clinical Research LLC, Oklahoma City, Oklahoma, United States
🇵🇷Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico
🇺🇸Mountain View Clinical Research, Inc, Greer, South Carolina, United States
Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 22
- Registration Number
- NCT02058095
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT01970176
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage
- Conditions
- Interventions
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT01960153
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Safety and Pharmacokinetic Interaction Study of Tadalafil and Dutasteride
- First Posted Date
- 2013-09-16
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Dongkook Pharmaceutical Co., Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT01942551
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.